Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has multiple approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational small molecule medicines in other serious diseases where it has deep insight into causal human biology, including pain, alpha-1 antitrypsin deficiency and APOL1-mediated kidney diseases. In addition, Vertex has a rapidly expanding pipeline of cell and genetic therapies for diseases such as sickle cell disease, beta thalassemia, Duchenne muscular dystrophy and type 1 diabetes mellitus.
Company profile
Ticker
VRTX
Exchange
Website
CEO
Reshma Kewalramani
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Vertex Pharmaceuticals (San Diego) LLC • Vertex Pharmaceuticals (Distribution) Incorporated • Vertex Pharmaceuticals (Cayman) Limited • Vertex Pharmaceuticals (Cayman III) Limited • Vertex Pharmaceuticals (Cayman 509) Limited • Vertex Pharmaceuticals (Cayman 765) Limited • Vertex Pharmaceuticals (Cayman 787) Limited • Vertex Pharmaceuticals (Delaware) LLC • Vertex Pharmaceuticals (Puerto Rico) LLC • Vertex Pharmaceuticals (Canada) Incorporated ...
IRS number
43039129
VRTX stock data
Analyst ratings and price targets
Latest filings (excl ownership)
10-K
2022 FY
Annual report
10 Feb 23
8-K
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
7 Feb 23
10-Q
2022 Q3
Quarterly report
28 Oct 22
8-K
Vertex Reports Third Quarter 2022 Financial Results
27 Oct 22
UPLOAD
Letter from SEC
4 Oct 22
CORRESP
Correspondence with SEC
26 Sep 22
UPLOAD
Letter from SEC
20 Sep 22
S-8
Registration of securities for employees
5 Aug 22
10-Q
2022 Q2
Quarterly report
5 Aug 22
8-K
Vertex Reports Second Quarter 2022 Financial Results
4 Aug 22
Transcripts
VRTX
Earnings call transcript
2022 Q4
7 Feb 23
VRTX
Earnings call transcript
2022 Q3
28 Oct 22
VRTX
Earnings call transcript
2022 Q2
5 Aug 22
VRTX
Earnings call transcript
2022 Q1
6 May 22
VRTX
Earnings call transcript
2021 Q4
27 Jan 22
VRTX
Earnings call transcript
2021 Q3
3 Nov 21
VRTX
Earnings call transcript
2021 Q2
30 Jul 21
VRTX
Earnings call transcript
2021 Q1
30 Apr 21
VRTX
Earnings call transcript
2020 Q4
2 Feb 21
VRTX
Earnings call transcript
2020 Q3
29 Oct 20
Latest ownership filings
144
Notice of proposed sale of securities
24 Mar 23
4
CHARLES F WAGNER JR
21 Mar 23
4
Bastiano Sanna
20 Mar 23
144
Notice of proposed sale of securities
17 Mar 23
144
Notice of proposed sale of securities
16 Mar 23
4
CHARLES F WAGNER JR
14 Mar 23
144
Notice of proposed sale of securities
13 Mar 23
144
Notice of proposed sale of securities
10 Mar 23
4
CHARLES F WAGNER JR
28 Feb 23
4
Ourania Tatsis
28 Feb 23
Financial summary
| Quarter (USD) | Dec 22 | Sep 22 | Jun 22 | Mar 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
73.7% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1169 |
| Opened positions | 179 |
| Closed positions | 92 |
| Increased positions | 411 |
| Reduced positions | 421 |
| 13F shares | Current |
|---|---|
| Total value | 67.72 tn |
| Total shares | 235.32 mm |
| Total puts | 984.04 k |
| Total calls | 1.09 mm |
| Total put/call ratio | 0.9 |
| Largest owners | Shares | Value |
|---|---|---|
| BLK Blackrock | 24.24 mm | $7.00 tn |
| Vanguard | 21.55 mm | $6.22 tn |
| FMR | 17.87 mm | $5.16 tn |
| Capital World Investors | 12.77 mm | $3.69 tn |
| STT State Street | 12.37 mm | $3.57 tn |
| Alliancebernstein | 9.07 mm | $2.62 tn |
| Wellington Management | 6.83 mm | $1.97 tn |
| JPM JPMorgan Chase & Co. | 5.49 mm | $1.58 tn |
| Geode Capital Management | 5.38 mm | $1.55 tn |
| Jennison Associates | 5.12 mm | $1.48 tn |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 301.13 | 16 | 4.82 k | 51,379 |
| 17 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 299.58 | 240 | 71.90 k | 51,395 |
| 17 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 298.09 | 360 | 107.31 k | 51,635 |
| 17 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 296.3 | 240 | 71.11 k | 51,995 |
| 17 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 295.43 | 784 | 231.62 k | 52,235 |
| 17 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 294.52 | 360 | 106.03 k | 53,019 |
| 16 Mar 23 | Bastiano Sanna | Common Stock | Sell | Dispose S | No | Yes | 301.07 | 264 | 79.48 k | 49,268 |
| 16 Mar 23 | Bastiano Sanna | Common Stock | Sell | Dispose S | No | Yes | 300.54 | 2,482 | 745.94 k | 49,532 |
| 13 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 296.77 | 62 | 18.40 k | 53,379 |
| 13 Mar 23 | Wagner Charles F JR | Common Stock | Sell | Dispose S | No | Yes | 295.89 | 292 | 86.40 k | 53,441 |
News
How Is The Market Feeling About Vertex Pharmaceuticals?
23 Mar 23
10 Analysts Have This to Say About Vertex Pharmaceuticals
21 Mar 23
Benzinga's Top Ratings Upgrades, Downgrades For March 21, 2023
21 Mar 23
Bernstein Initiates Coverage On Vertex Pharmaceuticals with Outperform Rating, Announces Price Target of $344
21 Mar 23
The FDA has Cleared Vertex Pharmaceuticals' Investigational New Drug Application For VX-264, Stem Cell-Derived Fully Differentiated Pancreatic Islet Cell Therapy Encapsulated Into Vertex-Developed, Immunoprotective Device For Type 1 Diabetes
9 Mar 23
Press releases
Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes
9 Mar 23
ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
1 Mar 23
Vertex to Present at Cowen's 43rd Annual Health Care Conference on March 7
21 Feb 23
Vertex Reports Fourth Quarter and Full Year Financial 2022 Results
7 Feb 23
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
3 Feb 23